Medshine Discovery Inc. has patented gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of endometriosis and uterine fibroids.
Medshine Discovery Inc. has patented substituted pyridine-2,4-dione derivatives acting as cardiac myosin inhibitors. As such, they are reported to be useful for the treatment of hypertrophic cardiomyopathy and heart failure.
Medshine Discovery Inc. has described gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of prostate cancer.
Medshine Discovery Inc. has patented new sulfinylpyridine-containing nonreceptor tyrosine-protein kinase TYK2 inhibitors expected to be useful for the treatment of Crohn's disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis and ulcerative colitis.
